Related Experiment Video
Updated: Jul 5, 2026
07:50
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.
1University of Oklahoma Health Sciences Center, Jimmy Everest Section of Pediatric Hematology/Oncology, University of Oklahoma Children's Physicians Building, Oklahoma City, OK 73104, USA. rene-mcnall@ouhsc.edu
Current Rheumatology Reports
|May 7, 2008
Summary
Antiphospholipid antibodies (aPL) target proteins in blood clotting, not phospholipids. Genetic factors and interactions with natural anticoagulants contribute to thrombosis in antiphospholipid syndrome.
Area of Science:
- Thrombosis and hemostasis research
- Immunology of autoimmune disorders
- Genetic predisposition to clotting disorders
Background:
- Antiphospholipid antibodies (aPL) are linked to thromboembolic events, but the exact thrombogenesis mechanism remains unclear.
- aPL pathogenic targets are plasma proteins like beta(2)-glycoprotein I and prothrombin, which bind to phospholipids.
- The hemostatic system's complexity requires more than single protein interruption for thrombosis.
Purpose of the Study:
- To review host genetic factors in aPL-associated thrombosis.
- To examine interactions between aPL and natural anticoagulants.
- To elucidate the mechanisms of thrombosis in antiphospholipid syndrome.
Main Methods:
- Literature review of studies on antiphospholipid antibodies and thrombosis.
- Analysis of host genetic factors influencing thrombosis risk.
- Examination of the interplay between aPL, plasma proteins, and the hemostatic system.
Main Results:
- Pathogenic targets of aPL are plasma proteins, leading to misclassification.
- Thrombosis in antiphospholipid syndrome involves complex interactions within the hemostatic system.
- Host genetic factors play a role in thrombosis predisposition.
Conclusions:
- Understanding aPL interactions with hemostatic proteins and genetic factors is crucial.
- Further research into these interactions may reveal new therapeutic targets.
- Clarifying thrombogenesis in antiphospholipid syndrome is essential for patient management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...